Biohaven Ltd.
- BHVN
- NYSE
- Biotechnology
- Neurology
- Immunology
- Clinical-Stage Biotech
$10.78
Today −5.69%Quote Oct 16, 2026, 08:00 PM UTC
−22.39%over the last month
Max drawdown −27.4%From 1-month high −27.4%3 months −27.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.63B
Quote Oct 16
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$20.00
+85.5% from here
Floor
$10.43
3.2% below price
Where the price sits
25 analysts
Analyst range, low to high
$11.00$30.00
- Price $10.78
- Resistance $11.26
- Consensus $20.00
Analysts' average target sits about 86% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BHVNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
274
Founded
2022